BlackRock, Inc. has officially notified that its direct and indirect ownership in Orion Oyj, a Finnish pharmaceutical company, has exceeded the 5% threshold as of June 4, 2026. This includes shares held directly, indirectly, and through financial instruments, totaling just over 5% of Orion's shares. The disclosure is made under Finnish securities law, signaling BlackRock's increased stake in Orion, which could influence investor confidence and company governance. Orion is known for its development and marketing of human and veterinary medicines, with a strong focus on cancer and pain therapies.
ISS A/S is actively executing its share buyback programme announced in February 2026, aiming to redistribute excess cash to shareholders by reducing share capital and fulfilling share-based incentive obligations. The company has repurchased shares wo...
Investec Bank plc, acting as joint broker to Gamma Communications Plc, disclosed its share transactions on October 9, 2026. The bank purchased 150,000 ordinary shares at prices between 1092.5 and 1094, while selling 167,967 shares at prices between 1...
Investec Bank Plc, acting as joint broker to SThree Plc, disclosed transactions involving the purchase and sale of 74,820 ordinary shares on October 9, 2026. The shares were traded at prices between 307.5 and 308.5 per unit. There were no derivative ...
Investec Bank plc, acting as advisor and broker to Gooch & Housego plc, disclosed the sale of 2,386 ordinary shares at a price of 1,230 per share on October 9, 2026. There were no derivative transactions or other dealing arrangements reported. This t...
FLSmidth & Co. A/S continued its share buy-back program initiated in May 2026, repurchasing 48,000 shares between October 5 and 8, 2026, at an average price ranging from DKK 548.31 to DKK 572.56 per share. The total value of shares bought back in thi...
